Involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 1, 2006, Pages 80-87

  Yamaguchi, Shoji ^a   Zhao, Ying Lan ^b,c   Nadai, Masayuki ^d   Yoshizumi, Hideo ^d   Cen, Xiaobo ^c   Torita, Shoko ^a   Takagi, Kenji ^a   Takagi, Kenzo ^a   Hasegawa, Takaaki ^b  

^a NAGOYA UNIVERSITY   (Japan)

^b AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c MEIJO UNIVERSITY   (Japan)

^d SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CYCLOSPORIN; DOXORUBICIN; GLYCOPROTEIN P; KETOLIDE; MULTIDRUG RESISTANCE PROTEIN 2; TELITHROMYCIN;

ANIMAL EXPERIMENT; ARTICLE; CANCER RESISTANCE; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG TRANSPORT; GENE OVEREXPRESSION; HEPATOBILIARY SYSTEM; HUMAN; HUMAN CELL; HYPERBILIRUBINEMIA; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; KETOLIDES; LIVER; MEMBRANE TRANSPORT PROTEINS; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 29944434375     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.1.80-87.2006     Document Type: Article

References (41)

1. Asakura, E., H. Nakayama, M. Sugie, Y. L. Zhao, M. Nadai, K. Kitaichi, A. Shimizu, M. Miyoshi, K. Takagi, K. Takagi, and T. Hasegawa. 2004. Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats. Eur. J. Pharmacol. 484:333-339.
2. Bearden, D. T., M. M. Neuhauser, and K. W. Garey. 2001. Telithromycin: an oral ketolide for respiratory infections. Pharmacotherapy 21:1204-1222.
3. Borst, P., R. Evers, M. Kool, and J. Wijnholds. 1999. The multidrug resistance protein family. Biochim. Biophys. Acta 1461:347-357.
4. Chen, Z. S., T. Kawabe, M. Ono, S. Aoki, T. Sumizawa, T. Furukawa, T. Uchiumi, M. Wada, M. Kuwano, and S. Akiyama. 1999. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol. Pharmacol. 56:1219-1228.
5. Endicott, J. A., and A. Ling. 1989. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 58:137-171.
6. Reference deleted.
7. Goeptar, A. R., J. M. Te Koppele, E. K. Lamme, J. M. Pique, and N. P. Vermeulen. 1993. Cytochrome P450 2B1-mediated one-electron reduction of adriamycin: a study with rat liver microsomes and purified enzymes. Mol. Pharmacol. 44:1267-1277.
8. Gorski, J. C., D. R. Jones, B. D. Haehner-Daniels, M. A. Hamman, E. M. O'Mara, and S. D. Hall. 1998. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin. Pharmacol. Ther. 64:133-143.
9. Gotoh, Y., H. Suzuki, S. Kinoshita, T. Hirohashi, Y. Kato, and Y. Sugiyama. 2000. Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats. J. Pharmacol. Exp. Ther. 292:433-439.
10. Hidemura, K., Y. L. Zhao, K. Ito, A. Naka, Y. Tatsumi, H. Kanazawa, K. Takagi, M. Ohta, and T. Hasegawa. 2003. Shiga-like toxin II impairs hepatobiliary transport of doxorubicin in rats by down-regulation of hepatic P glycoprotein and multidrug resistance-associated protein Mrp2. Antimicrob. Agents Chemother. 47:1636-1642.
11. Kiso, S., S. H. Cai, K. Kitaichi, N. Furui, K. Takagi, K. Takagi, T. Nabeshima, and T. Hasegawa. 2000. Inhibitory effect of erythromycin on P-glycoprotein-mediated biliary excretion of doxorubicin in rats. Anticancer Res. 20:2827-2834.
12. König, J., A. T. Nies, Y. Cui, I. Leier, and D. Keppler. 1999. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim. Biophys. Acta 1461:377-394.
13. Kool, M., M. de Haas, G. L. Scheffer, R. J. Scheper, M. J. van Eijk, J. A. Juijin, F. Baas, and P. Borst. 1997. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance- associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 57:3537-3547.
14. Mayer, R., J. Kartenheck, M. Buchler, G. Jedlitschky, I. Leier, and D. Kuppler. 1995. Expression of the MRP gene-encoded conjugate export pump in liver and its selective absence from the canalicular membrane in transport-deficient mutant hepatocytes. J. Cell Biol. 131:137-150.
15. Newton, D. J., R. W. Wang, and D. C. Evans. 2005. Determination of phase I metabolic enzyme activities in liver microsomes of Mrp2 deficient TR- and EHBR rats. Life Sci. 77:1106-1115.
16. Nishaminy, K., and S. A. Pinak. 2005. Telithromycin: the first ketolide for the treatment of respiratory infections. Am. J. Health-Syst. Pharm. 62:905-916.
17. Ohmori, S., S. Kuriya, T. Uesugi, T. Horie, F. Sagami, T. Mikami, A. Kawaguchi, T. Rikihisa, and Y. Kanakubo. 1991. Decrease in the specific forms of cytochrome P-450 in liver microsomes of a mutant strain of rat with hyperbilirubinuria. Res. Commun. Chem. Pathol. Pharmacol. 72:243-253.
18. Oude Elferink, R. P., D. K. Meijer, F. Kuipers, P. L. Jansen, A. K. Groen, and G. M. Groothuis. 1995. Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport. Biochim. Biophys. Acta 1241:215-268.
19. Pachot, J. I., R. P. Botham, K. D. Haegele, and K. Hwang. 2003. Experimental estimation of the role of P-glycoprotein in the pharmacokinetic behaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco-2 cell model. J. Pharm. Pharm. Sci. 6:1-12.
20. Periti, P., T. Mazzei, E. Mini, and A. Novelli. 1992. Pharmacokinetic drug interactions of macrolides. Clin. Pharmacokinet. 23:106-131.
21. Reed, M., G. C. Wall, N. P. Shah, J. M. Heun, and G. A. Hicklin. 2005. Verapamil toxicity resulting from a probable interaction with telithromycin. Ann. Pharmacother. 39:357-360.
22. Scheinfeld, N. 2004. Telithromycin: a brief review of a new ketolide antibiotic. J. Drugs Dermatol. 3:409-413.
23. Schinkel, A. H., U. Mayer, E. Wagenaar, C. A. Mol, L. van Deemter, J. J. Smith, M. A. van der Valk, A. C. Voordouw, H. Spits, O. van Tellingen, J. M. Zijlmans, W. E. Fibbe, and P. Borst. 1997. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. USA 94:4028-4032.
24. Schinkel, A. H., E. Wagenaar, C. A. Mol, and L. van Deemter. 1996. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Investig. 97:2517-2524.
25. Seral, C., J. M. Michot, H. Chanteux, M. P. Mingeot-Leclercq, P. M. Tulkens, and F. van Bambeke. 2003. Influence of P-glycoprotein inhibitors on accumulation of macrolides in J774 murine macrophages. Antimicrob. Agents Chemother. 47:1047-1051.
26. Shain, C. S., and G. W. Amsden. 2002. Telithromycin: the first of the ketolides. Ann. Pharmacother. 36:452-464.
27. Sharom, F. J., X. Yu, and C. A. Doige. 1993. Functional reconstitution of drug transport and ATPase activity in proteoliposomes containing partially purified P-glycoprotein. J. Biol. Chem. 268:197-202.
28. Shi, J., G. Montay, B. Leroy, and V. O. Bhargava. 2005. Effects of itraconazole or grapefruit juice on the pharmacokinetics of telithromycin. Pharmacotherapy 25:42-51.
29. Spiers, K. M., and M. J. Zervos. 2004. Telithromycin. Exp. Rev. Anti-Infect. Ther. 2:685-693.
30. Sugie, M., E. Asakura, Y.L. Zhao, S. Torita, M. Nadai, K. Baba, K. Kitaichi, K. Takagi, and T. Hasegawa. 2004. Possible involvement of drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin. Antimicrob. Agents Chemother. 48:809-814.
31. Takenaka, O., T. Horie, K. Kobayashi, H. Suzuki, and Y. Sugiyama. 1995. Kinetic analysis of hepatobiliary transport for conjugated metabolites in the perfused liver of mutant rats (EHBR) with hereditary conjugated hyperbilirubinemia. Pharm. Res. 12:1746-1755.
32. Takenaka, O., T. Horie, H. Suzuki, and Y. Sugiyama. 1995. Different biliary excretion systems for glucuronide and sulfate of a model compound; study using Eisai hyperbilirubinemic rats. J. Pharmacol. Exp. Ther. 274:1362-1369.
33. Thiebaut, F., T. Tsuruo, H. Hamada, M. M. Gottesman, I. Pastan, and M. C. Willingham. 1987. Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 84:7735-7738.
34. Tsuruo, T., H. Iida, S. Tsukagoshi, and Y. Sakurai. 1981. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41:1967-1972.
35. Tsuruo, T., H. Iida, S. Tsukagoshi, and Y. Sakurai. 1982. Increased accumulation of vincristine and adriamycin in drug-resistant tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res. 42:4730-4733.
36. Twentyman, P. R., N. E. Fox, and D. J. White. 1987. Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multidrug resistant human lung cancer cell line. Br. J. Cancer 56:55-57.
37. Wacher, V. J., C. Y. Wu, and L. Z. Benet. 1995. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 13:129-134.
38. Wakasugi, H., I. Yano, T. Ito, T. Hashida, T. Futami, R. Nohara, S. Sasayama, and K. Inui. 1998. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin. Pharmacol. Ther. 64:123-128.
39. Wang, L., K. Kitaichi, S. H. Cai, K. Takagi, K. Takagi, M. Sakai, L. Yokogawa, K.-I. Miyamoto, and T. Hasegawa. 2000. Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo. Clin. Exp. Pharmacol. Physiol. 27:587-593.
40. Yumoto, R., T. Murakami, Y. Nakamoto, R. Hasegawa, J. Nagai, and M. Takano. 1999. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. J. Exp. Pharmacol. Ther. 289:149-155.
41. Zhanel, G. G., M. Walters, A. Noreddin, L. M. Vercaigne, A. Wierzbowski, J. M. Embil, A. S. Gin, S. Douthwaite, and D. J. Hoban. 2002. The ketolides: a critical review. Drugs 62:1771-1804.